Europe Addresses Antibiotic Resistance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Europe Addresses Antibiotic Resistance


Pharmaceutical Technology Europe
Volume 22, Issue 12

In summary

Antibiotic resistance remains a very serious threat due to the limitations of current agents and poor public knowledge about bacterial infections. The European Antibiotic Awareness Day campaign represents a continuing effort to combat these problems across the region, but measures are also needed to boost new pharmaceutical industry R&D efforts. Although the 2009 European Observatory on Health Systems and Policies report was a welcome step forward in summarising thinking of how to stimulate new industry research, it has not yet prompted governments to implement specific incentives. In 2009, a survey among European intensive care physicians found that 53% had treated at least one patient infected with a bacterium totally or almost totally resistant to available antibiotics during the previous 6 months.10 Worrying developments such as these are a warning that governments must bring a sense of urgency to incentivising new antibiotic R&D efforts.

References

1. About European Antibiotic Awareness Day (2008). antibiotic2008.ecdc.europa.eu

2. The overuse of antibiotics — Eurobarometer statistics. http://efpia.blogspot.com/

3. E. Mossialos, et al., Policies and incentives for promoting innovation in antibiotic research (2010). http://www.euro.who.int/

4. Antimicrobial Resistance, Eurobarometer 72.5 (2009). ec.europa.eu

5. Les Antibiotiques, Eurobarometer Special (2003). ec.europa.eu

6. C.A.M. McNulty, J. Antimicrob. Chemo., 65,1526-1533 (2010).

7. S. Coenen, et al., Acta Clinica Belgica, 63-5 (2008).

8. B. Huttner. Antibiotics Are Not Automatic Anymore — The French National Campaign To Cut Antibiotic Overuse. PLoS Medicine 6(6) (2009). http://www.plosmedicine.org/

9. L. Jarvis, An Uphill Battle (2008). http://pubs.acs.org/cen/

10. A. Lepape, Eurosurveillance, 14(45), 12 (2009). http://www.eurosurveillance.org/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology Europe,
Click here